(Q34326528)

1 August 2017

1 reference

title

Thalidomide in the management of multiple myeloma. (English)

1 reference

1 August 2017

0 references

Barlogie B

1

1 reference

1 August 2017

Zangari M

2

1 reference

1 August 2017

Spencer T

3

1 reference

1 August 2017

Fassas A

4

1 reference

1 August 2017

Anaissie E

5

1 reference

1 August 2017

Badros A

6

1 reference

1 August 2017

Cromer J

7

1 reference

1 August 2017

Tricot G

8

1 reference

1 August 2017

1 July 2001

1 reference

1 August 2017

Seminars in Hematology

1 reference

1 August 2017

38

1 reference

1 August 2017

250-259

1 reference

1 August 2017

3

1 reference

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990017-4

7 January 2021

10.1016/S0037-1963(01)90017-4

Identifiers

DOI

1 reference

release_4fbbsuk3cfbollhapa4agcopqi

1 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4fbbsuk3cfbollhapa4agcopqi

24 November 2022

mapped directly with Wikidata item

1 reference